Back to Dashboard
COYA · Healthcare

COSTAR GROUP INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Moderate — mixed signals

No standout activity across the feeds we track.

Hedge funds
73
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Limited info. COSTAR GROUP INC is not currently in our model portfolio, but 12 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$106M
Industry
Biotechnology
Exchange
NasdaqCM
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as…
12
Investors
3
New positions
6
Increasing
2
Decreasing
1
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Viking Global Investors
Trust weight: 1.5×
New position
% of portfolio
0.3%
Position change
NEW
0.3% of Viking Global Investors's portfolio
Tudor Investment (Paul Tudor Jones)
Trust weight: 1.2×
New position
% of portfolio
0.1%
Position change
NEW
0.1% of Tudor Investment's portfolio
Bridgewater Associates (Dalio)
Trust weight: 1.3×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of Bridgewater Associates's portfolio
Akre Capital Management (Akre)
Trust weight: 1.5×
Increased +3%
% of portfolio
7.1%
Position change
+3%
7.1% of Akre Capital Management's portfolio
Third Point (Loeb)
Trust weight: 1.2×
Increased +5%
% of portfolio
2.9%
Position change
+5%
2.9% of Third Point's portfolio
Baillie Gifford & Co
Trust weight: 1.4×
Increased +57%
% of portfolio
0.7%
Position change
+57%
0.7% of Baillie Gifford & Co's portfolio
Gotham Asset Mgmt (Greenblatt)
Trust weight: 1.1×
Increased +476%
% of portfolio
0.0%
Position change
+476%
0.0% of Gotham Asset Mgmt's portfolio
Millennium Management (Englander)
Trust weight: 1.0×
Increased +47%
% of portfolio
0.0%
Position change
+47%
0.0% of Millennium Management's portfolio
AQR Capital Management
Trust weight: 1.0×
Increased +14%
% of portfolio
0.0%
Position change
+14%
0.0% of AQR Capital Management's portfolio
Tiger Global Management
Trust weight: 1.4×
Decreased −30%
% of portfolio
0.5%
Position change
−30%
0.5% of Tiger Global Management's portfolio
D.E. Shaw & Co
Trust weight: 1.0×
Unchanged
% of portfolio
0.1%
Position change
—
0.1% of D.E. Shaw & Co's portfolio
Citadel Advisors
Trust weight: 1.0×
Decreased −65%
% of portfolio
0.0%
Position change
−65%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to COSTAR GROUP INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COSTAR GROUP INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
© 2026 Bogen Capital  ·  Not financial advice  ·  Data delayed up to 135 days Methodology  ·  Contact  ·  API